Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk

  • Cho, Yun-Kyeong (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Hur, Seung-Ho (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Han, Chun-Duk (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Park, Hyoung-Seob (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Yoon, Hyuck-Jun (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Kim, Hyung-Seop (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Nam, Chang-Wook (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Kim, Yoon-Nyun (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Kim, Kwon-Bae (Department of Internal Medicine, Keimyung University Dongsan Hospital) ;
  • Park, Nam-Hee (Department of Thoracic and Cardiovascular Surgery, Keimyung University Dongsan Hospital) ;
  • Park, Hee-Jun (Department of Medical Informatics, Keimyung University Dongsan Hospital)
  • Published : 2011.03.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Although recent lipid-lowering therapies are effective in reducing low density lipoprotein-cholesterol (LDL-C) levels, many patients treated with lipid-lowering agents do not achieve target LDL-C levels, especially in very high risk patients. The aim of this study is to compare the effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg on achieving a target LDL-C goal in very high risk patients. Subjects and Methods: A total of 74 patients with very high risk were enrolled in the study. Very high risk patients were defined as patients that displayed established cardiovascular disease with multiple major risk factors, poorly controlled risk factors, multiple risk factors of the metabolic syndrome and acute coronary syndromes. Patients were randomized into two groups: ezetimibe/simvastatin 10/20 mg (n=36) and atorvastatin 20 mg (n=38). Follow-up lipid profile was obtained 6 weeks later. A target goal of LDL-C was defined as less than 70 mg/dL at follow-up. Results: Baseline clinical and laboratory data were similar between the two groups. Achieving a target LDL-C goal was observed in 41.7% of Group 1 and 44.7% of Group 2 at 6 weeks (p=0.82). Changes in other lipid profiles were not significantly different but the tolerability of the two groups was similar. Conclusion: Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg showed similar effects in achieving target LDL-C levels in patients with very high risk.

Keywords

References

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. https://doi.org/10.1001/jama.285.19.2486
  2. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979;90:85-91. https://doi.org/10.7326/0003-4819-90-1-85
  3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  4. Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283: 157-63.
  5. Van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH 58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129: 1748-54. https://doi.org/10.1038/sj.bjp.0703235
  6. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34. https://doi.org/10.1016/S0735-1097(02)02610-4
  7. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with si-mvastatin in patients with primary hypercholesterolemia: a randomiz-ed, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79: 620-9. https://doi.org/10.4065/79.5.620
  8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23-33. https://doi.org/10.1016/S0140-6736(02)09328-5
  9. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. https://doi.org/10.1056/NEJMoa040583
  10. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73. https://doi.org/10.1016/j.ahj.2004.11.023
  11. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-16. https://doi.org/10.1016/S0140-6736(03)13636-7
  12. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocar-dial Infarction 22 trials). Am J Cardiol 2007;100:1047-51. https://doi.org/10.1016/j.amjcard.2007.04.053
  13. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007;30(Suppl 1):S4-41.
  14. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006;81:1579-88. https://doi.org/10.4065/81.12.1579
  15. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32. https://doi.org/10.1016/j.ahj.2008.07.023
  16. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78. https://doi.org/10.1016/S0140-6736(05)67394-1
  17. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94. https://doi.org/10.1016/j.amjcard.2004.02.060
  18. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746-55. https://doi.org/10.1111/j.1368-5031.2004.00289.x
  19. Yun KH, Park HY, Choi JH, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10 mg versus atorvastatin 20 mg. Korean Circ J 2007;37:154-60. https://doi.org/10.4070/kcj.2007.37.4.154

Cited by

  1. Threshold Level of Low-Density Lipoprotein Cholesterol for the Short-Term Benefit of Statin Therapy in the Acute Phase of Myocardial Infarction vol.35, pp.4, 2012, https://doi.org/10.1002/clc.20984
  2. Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults vol.11, pp.None, 2012, https://doi.org/10.1186/1475-2840-11-55
  3. Relationship Between Statin Type and Responsiveness to Clopidogrel in Patients Treated with Percutaneous Coronary Intervention: A Subgroup Analysis of the CILON-T Trial vol.21, pp.2, 2011, https://doi.org/10.5551/jat.19265